Welcome to our dedicated page for Kazia Therapeuti SEC filings (Ticker: KZIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kazia Therapeutics Limited (NASDAQ: KZIA) files as a foreign private issuer with the U.S. Securities and Exchange Commission, primarily using Form 20-F for annual reporting and Form 6-K for current reports. This SEC filings page for KZIA brings together those regulatory documents and pairs them with AI-generated summaries to help readers interpret the company’s disclosures.
For a clinical-stage oncology company like Kazia, Form 6-K reports often incorporate press releases and transaction details by reference. Recent 6-K filings describe private placements of equity securities, the terms of pre-funded warrants and American Depositary Shares, at-the-market offering agreements, and collaboration and in-licensing arrangements such as the PD-L1 protein degrader program with QIMR Berghofer. Other 6-Ks discuss Nasdaq listing notices, the company’s responses, and subsequent steps taken to regain or demonstrate compliance with listing standards.
These filings also reference how capital raised is intended to support the continued clinical development of Kazia’s lead programs, including paxalisib, a brain-penetrant PI3K / Akt / mTOR pathway inhibitor, and EVT801, a VEGFR3 inhibitor, as well as the PD-L1 degrader program. Supplemental risk factor disclosures in certain filings provide additional detail on regulatory approval processes, combination therapy development, and ongoing regulatory obligations after any potential approvals.
On this page, AI-powered tools can help explain the structure and implications of Kazia’s 6-K filings, highlight key terms in financing agreements, and summarize how new collaborations or regulatory updates relate to the company’s oncology pipeline. Users can also review references to incorporated press releases, understand how offerings may affect capital structure, and see how Kazia describes its strategy for maintaining Nasdaq listing and advancing its investigational cancer therapies.
Kazia Therapeutics executive David Cain filed an initial ownership report showing he holds several stock option awards. These include options over 5,000 American Depositary Shares at an exercise price of $19.0000 and 100,000 ADS at $8.0000, plus options over 100,000 and 400,000 Ordinary Shares at exercise prices of $0.6651 and $0.1061. The options vest in scheduled annual or quarterly installments, contingent on his continued service, and expire between February 1, 2027 and July 22, 2027.
Kazia Therapeutics Limited filed a prospectus supplement to update its Form F-1 registration for 95,110 American Depositary Shares representing 47,555,000 Ordinary Shares, referencing a Form 6-K dated March 31, 2026. The supplement attaches a March 27, 2026 investor presentation and fact sheet and notes a board change: Chairman Bryce Carmine resigned effective March 31, 2026, reducing the board from four to three directors. The company reported the re-election of Steven Coffey with 1,050,412,780 votes for.
Kazia Therapeutics Limited files a prospectus supplement registering 10,700,211 American Depositary Shares, representing 5,350,105,500 Ordinary Shares, and furnishes a Form 6-K dated March 31, 2026. The supplement attaches an investor presentation and fact sheet dated March 27, 2026 and notes the ADS last sale price of $7.31 per ADS.
The Form 6-K reports the resignation of Chairman Bryce Carmine effective March 31, 2026, a reduction in Board size from four to three directors, appointment of Ebru Davidson to the Audit, Risk and Governance Committee, and shareholder re-election of Steven Coffey at the AGM.
Kazia Therapeutics Limited filed a prospectus supplement updating its Form F-1 registration to reflect a Form 6-K furnished March 31, 2026. The supplement covers 266,666 ADSs representing 133,333,000 Ordinary Shares and states the ADSs trade on Nasdaq under the symbol KZIA. The company reported the March 25, 2026 Annual General Meeting approved the re-election of Steven Coffey with 1,050,412,780 votes for, and noted the resignation of Chairman Bryce Carmine effective March 31, 2026, reducing the Board from four to three directors.
Kazia Therapeutics Limited files a prospectus supplement registering 232,956 American Depositary Shares (ADSs). The supplement attaches a Form 6-K dated March 31, 2026 and updates the Prospectus dated December 23, 2025.
The Form 6-K discloses the resignation of Chairman Bryce Carmine effective March 31, 2026, the Board shrinking from four to three directors, appointment of Ebru Davidson to the Audit, Risk and Governance Committee, and AGM vote results re‑electing Steven Coffey (1,050,412,780 for; 3,637,588 against; 1,289,127 abstain). The ADSs trade on Nasdaq under symbol KZIA (last reported sale $7.31 per ADS).
Kazia Therapeutics Limited reports board changes, shareholder voting outcomes, and shares an updated corporate overview. Chairman Bryce Carmine will retire effective March 31, 2026, and the board will shrink from four to three directors, with Ebru Davidson joining the Audit, Risk and Governance Committee. The company states his resignation is not due to any disagreement over operations or policies. Shareholders re-elected director Steven Coffey, with 1,050,412,780 votes for and 3,637,588 against.
Kazia also furnishes a detailed investor presentation and fact sheet outlining its oncology pipeline. Lead asset paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor, has been studied in more than 550 patients and is being advanced in glioblastoma, pediatric brain cancers, brain metastases, and triple negative breast cancer, where early Phase 1b data include one complete metabolic response and two partial responses. The company highlights cash and cash equivalents of about US$46 million, no debt, and an expected cash runway into 2029, as well as a preclinical PD-L1 protein degrader (NDL2) and VEGFR3 inhibitor EVT801.
Kazia Therapeutics Ltd ownership update: A Schedule 13G/A amendment reports that Jorey Chernett beneficially owned 1,588,129 American Depositary Shares as of the close of business on 02/19/2026, representing 13.90% of the class based on 11,426,899 ADS outstanding as of 03/12/2026.
The filing lists sole voting and dispositive power over those ADS and is signed on 03/31/2026.
Kazia Therapeutics Ltd reported that Alumni Capital LP, Alumni Capital GP LLC and Ashkan Mapar hold no American Depository Shares as of January 30, 2026. This Amendment No. 5 Schedule 13G/A functions as an exit filing, showing 0 shares and 0% ownership for each reporting person.
The filing lists the reporting persons' principal business address and confirms the General Partner and controlling person relationships; signatures are dated March 30, 2026.
Kazia Therapeutics Limited reported an unaudited half‑year loss of $12,552,490 for the six months ended 31 December 2025, wider than the prior period’s $10,453,811. Operating cash outflow was $9,540,623, but cash and cash equivalents rose sharply to $69,459,980 as of 31 December 2025 after substantial equity financing.
The company strengthened its balance sheet via private placements, including an approximately $50.0 million equity financing in December 2025 and issuance of pre‑funded warrants, and ended the period with net assets of $46,467,039. R&D focused on paxalisib in breast cancer and glioblastoma, alongside an in‑licensed PD‑L1 degrader program. The auditor’s review raised no independence issues.
Subsequently, Kazia entered a new at‑the‑market equity Sales Agreement with Leerink Partners LLC, allowing periodic sales of American Depositary Shares under an effective Form F‑3 shelf registration, and terminated its prior at‑the‑market program with Rodman & Renshaw LLC.